Transgene SA
PAR:TNG

Watchlist Manager
Transgene SA Logo
Transgene SA
PAR:TNG
Watchlist
Price: 0.702 EUR
Market Cap: 92.9m EUR
Have any thoughts about
Transgene SA?
Write Note

Transgene SA
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Transgene SA
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Transgene SA
PAR:TNG
Revenue
€7.8m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Valneva SE
PAR:VLA
Revenue
€229.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Innate Pharma SA
PAR:IPH
Revenue
€24.9m
CAGR 3-Years
-10%
CAGR 5-Years
-26%
CAGR 10-Years
11%
G
Genfit SA
PAR:GNFT
Revenue
€84m
CAGR 3-Years
151%
CAGR 5-Years
61%
CAGR 10-Years
29%
Inventiva SA
PAR:IVA
Revenue
€15.6m
CAGR 3-Years
255%
CAGR 5-Years
37%
CAGR 10-Years
N/A
Eurobio Scientific SA
PAR:ALERS
Revenue
€144.2m
CAGR 3-Years
-13%
CAGR 5-Years
21%
CAGR 10-Years
17%
No Stocks Found

Transgene SA
Glance View

Market Cap
92.9m EUR
Industry
Biotechnology

Transgene SA is a clinical-stage biotechnology company, which engages in the research, development, and manufacture of immunotherapies for the treatment of cancer and infectious diseases. The company is headquartered in Illkirch-Graffenstaden, Grand Est and currently employs 167 full-time employees. The firm designs and develops immunotherapy products to treat cancer and infectious diseases. These products use viral vectors to directly or indirectly destroy diseased cells. The firm has approximately three products in clinical development: two immunotherapy products for cancer treatment and an anti-infective immunotherapy product for chronic hepatitis B. The firm also has various other programs based on its viral vector technology in research or in pre-clinical or clinical development. The firm's activities are focused on human health and, in particular, the research and development of immunotherapy products, including therapeutic vaccines and oncolytic viruses in the field of cancer and infectious diseases. The firm's principal products include TG4010 (MVA-MUC1-IL2), Pexa-Vec (VV-TK-GM-CSF), TG6002 (VV-TK-RR-FCU1), TG1050 (Ad5-HBV) and TG4001 (MVA-HPV-IL2).

TNG Intrinsic Value
1.023 EUR
Undervaluation 31%
Intrinsic Value
Price

See Also

What is Transgene SA's Revenue?
Revenue
7.8m EUR

Based on the financial report for Sep 30, 2024, Transgene SA's Revenue amounts to 7.8m EUR.

Back to Top